<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467113</url>
  </required_header>
  <id_info>
    <org_study_id>ZX008-1602</org_study_id>
    <nct_id>NCT03467113</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol</brief_title>
  <official_title>An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with&#xD;
      Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered cannabidiol&#xD;
      (CBD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Actual">June 24, 2020</completion_date>
  <primary_completion_date type="Actual">June 24, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline to Day 365</time_frame>
    <description>Number of adverse events including serious adverse events, number of adverse events leading to study withdrawal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>Baseline to Day 365</time_frame>
    <description>Change in resting heart rate using standard measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline to Day 365</time_frame>
    <description>Change in resting blood pressure using standard measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in temperature</measure>
    <time_frame>Baseline to Day 365</time_frame>
    <description>Change in resting temperature using standard measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory rate</measure>
    <time_frame>Baseline to Day 365</time_frame>
    <description>Change in resting respiratory rate using standard measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in heart rhythm</measure>
    <time_frame>Baseline to Day 365</time_frame>
    <description>Changes in heart beat as measured with 12-lead electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in heart valve function</measure>
    <time_frame>Baseline to Day 365</time_frame>
    <description>Changes in heart valves as measured with standard echocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in treatment-emergent body weight and height</measure>
    <time_frame>Baseline to Day 365</time_frame>
    <description>Changes in body weight and height by report of BMI in kg/m^2</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Dravet Syndrome</condition>
  <condition>Lennox Gastaut Syndrome</condition>
  <arm_group>
    <arm_group_label>ZX008 0.2 to 0.8 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (flexible dosing 0.2 mg/kg/day to 0.8 mg/kg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZX008 0.2 to 0.8 mg/kg/day</intervention_name>
    <description>ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.</description>
    <arm_group_label>ZX008 0.2 to 0.8 mg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Cannabidiol</description>
    <arm_group_label>ZX008 0.2 to 0.8 mg/kg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a clinical diagnosis of DS or LGS, where convulsive seizures (generalized&#xD;
             tonic clonic seizures, tonic seizures, atonic seizures, tonic/atonic seizures, focal&#xD;
             seizures with clear observable motor signs) are not completely controlled by current&#xD;
             AEDs.&#xD;
&#xD;
          -  All medications or interventions for epilepsy (including ketogenic diet [KD] and vagal&#xD;
             nerve stimulation [VNS]) must be stable for at least 4 weeks prior to first ZX008 dose&#xD;
             and are expected to remain stable throughout the study.&#xD;
&#xD;
          -  Subjects must be taking a stable dose of CBD for at least 4 weeks prior to first ZX008&#xD;
             dose.&#xD;
&#xD;
          -  Subject's source of CBD is expected to be consistent for at least 3 months during&#xD;
             study participation.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Subject has current or past history of cardiovascular or cerebrovascular disease,&#xD;
             myocardial infarction or stroke.&#xD;
&#xD;
          -  Subject with current cardiac valvulopathy or pulmonary hypertension that the&#xD;
             Investigator, parent/caregiver, Independent Cardiac Advisory Board, Independent Data&#xD;
             and Safety Monitoring Committee, or sponsor deems clinically significant.&#xD;
&#xD;
          -  Subject has a current or past history of glaucoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PANDA Neurology/CIRCA</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research &amp; Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <disposition_first_submitted>June 23, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>June 23, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 25, 2021</disposition_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dravet Syndrome</keyword>
  <keyword>LGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
    <mesh_term>Lennox Gastaut Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

